Bausch + Lomb Corporation

NYSE:BLCO Stock Report

Market Cap: US$6.0b

Bausch + Lomb Valuation

Is BLCO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BLCO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BLCO ($16.35) is trading below our estimate of future cash flow value ($33.85)

Significantly Below Future Cash Flow Value: BLCO is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BLCO?

Key metric: As BLCO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BLCO. This is calculated by dividing BLCO's market cap by their current revenue.
What is BLCO's PS Ratio?
PS Ratio1.1x
SalesUS$5.32b
Market CapUS$5.99b

Price to Sales Ratio vs Peers

How does BLCO's PS Ratio compare to its peers?

The above table shows the PS ratio for BLCO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
LNTH Lantheus Holdings
4.3x7.83%US$6.6b
MMED MiniMed Group
1.7x8.79%US$5.2b
MMSI Merit Medical Systems
3.3x5.89%US$5.1b
HAE Haemonetics
2.9x5.56%US$3.8b
BLCO Bausch + Lomb
1.1x5.43%US$6.0b

Price-To-Sales vs Peers: BLCO is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does BLCO's PS Ratio compare vs other companies in the US Medical Equipment Industry?

49 CompaniesPrice / SalesEstimated GrowthMarket Cap
QDEL QuidelOrtho
0.4x3.28%US$1.20b
OFIX Orthofix Medical
0.5x4.03%US$424.43m
NVRO Nevro
0.5x3.58%US$221.21m
EMBC Embecta
0.2x1.69%US$211.80m
BLCO 1.1xIndustry Avg. 2.9xNo. of Companies49PS02.44.87.29.612+
49 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BLCO is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Medical Equipment industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is BLCO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLCO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: BLCO is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BLCO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.35
US$18.63
+13.91%
12.83%US$23.00US$16.00n/a12
Jul ’27US$16.55
US$17.88
+8.01%
9.96%US$21.00US$16.00n/a12
Jun ’27US$15.39
US$17.88
+16.15%
9.96%US$21.00US$16.00n/a12
May ’27US$16.31
US$18.04
+10.60%
9.99%US$21.00US$16.00n/a13
Apr ’27US$16.68
US$18.46
+10.68%
10.16%US$21.00US$15.00n/a13
Mar ’27US$18.30
US$18.64
+1.87%
10.31%US$21.00US$15.00n/a14
Feb ’27US$16.70
US$17.54
+5.00%
13.74%US$21.00US$13.00n/a14
Jan ’27US$17.08
US$17.25
+1.00%
12.81%US$21.00US$13.00n/a14
Dec ’26US$16.56
US$16.63
+0.44%
11.64%US$20.00US$13.00n/a15
Nov ’26US$14.94
US$16.30
+9.10%
10.01%US$19.00US$13.00n/a15
Oct ’26US$14.67
US$15.20
+3.61%
13.47%US$18.00US$12.00n/a15
Sep ’26US$14.63
US$15.14
+3.51%
13.92%US$18.00US$12.00n/a14
Aug ’26US$13.50
US$15.00
+11.11%
15.38%US$18.00US$11.00US$16.9114
Jul ’26US$13.45
US$14.29
+6.21%
18.17%US$18.00US$11.00US$16.5514
Jun ’26US$11.47
US$14.50
+26.42%
19.59%US$19.00US$11.00US$15.3914
May ’26US$11.59
US$15.29
+31.89%
20.71%US$20.00US$11.00US$16.3114
Apr ’26US$14.10
US$18.86
+33.74%
12.65%US$25.00US$15.00US$16.6814
Mar ’26US$16.00
US$19.46
+21.65%
12.28%US$25.00US$17.00US$18.3015
Feb ’26US$17.35
US$20.66
+19.10%
11.41%US$25.00US$18.00US$16.7015
Jan ’26US$18.06
US$21.06
+16.64%
13.37%US$26.00US$18.00US$17.0815
Dec ’25US$19.82
US$21.43
+8.11%
13.41%US$26.00US$18.00US$16.5614
Nov ’25US$20.51
US$21.43
+4.47%
13.41%US$26.00US$18.00US$14.9414
Oct ’25US$19.14
US$20.20
+5.53%
10.73%US$25.00US$18.00US$14.6715
Sep ’25US$16.43
US$19.73
+20.11%
12.34%US$25.00US$16.00US$14.6315
Aug ’25US$16.86
US$19.80
+17.44%
12.26%US$25.00US$16.00US$13.5015
US$18.63
Fair Value
12.2% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/06 21:27
End of Day Share Price 2026/08/06 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bausch + Lomb Corporation is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBofA Global Research
Joanne WuenschCitigroup Inc
Philip ChickeringDeutsche Bank